NASDAQ: SABS
SAB Biotherapeutics, Inc.
Healthcare · Biotechnology
After hours: $3.79(0%) · as of 4:10 PM ET
Market Cap
$344.84M
52w High
$5.15
52w Low
$1.85
P/E
17.51
Volume
351.10K
Outstanding Shares
90.99M
Performance
Return analysis
Price vs Fundamentals
Why The Stock Is Moving
What changed
The stock rose 73.85% over the last year. Revenue declined 100% over the trailing twelve months. Free cash flow declined 137.04% over the trailing twelve months.
What the market seems to be pricing
The stock has moved higher against modestly weakening underlying metrics. The operating data does not yet tell a clear story — the move may reflect sentiment, sector rotation, or macro factors rather than company-specific earnings power.
What would invalidate this read
A decisive move in revenue — currently down 100% — would be the clearest signal to resolve the ambiguity.
Company profile
SAB Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of human polyclonal immunotherapeutic antibodies to address immune system disorders and infectious diseases in the United States.
Valuation
Stock splits
Every 10 shares became 1
Profitability & growth
Analyst consensus
7
Buy
1
Hold
0
Sell
Analyst ratings tend to be lagging indicators. Use as one signal among many.
Earnings
Full quarter-by-quarter history of actuals vs estimates. Switch into compare mode to inspect one metric year-over-year.
Next report
Nov 13, 2026
Q4 FY26 · EPS est -$0.27 · Revenue est $125K
View